393 related articles for article (PubMed ID: 29307892)
1. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
Wanner C
Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
[No Abstract] [Full Text] [Related]
2. Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
Ingelfinger JR; Rosen CJ
N Engl J Med; 2016 Jul; 375(4):380-2. PubMed ID: 27331286
[No Abstract] [Full Text] [Related]
3. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
Hocher B; Tsuprykov O
Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
[No Abstract] [Full Text] [Related]
4. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.
Bell RM; Yellon DM
Lancet Diabetes Endocrinol; 2018 Jun; 6(6):435-437. PubMed ID: 29030201
[No Abstract] [Full Text] [Related]
5. Introduction.
Chilton RJ
Am J Cardiol; 2017 Jul; 120(1S):S1-S3. PubMed ID: 28606339
[No Abstract] [Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
Goldberg N; Fralick M
CMAJ; 2017 May; 189(20):E724. PubMed ID: 28536128
[No Abstract] [Full Text] [Related]
7. Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias.
Suissa S
Circulation; 2018 Apr; 137(14):1432-1434. PubMed ID: 29610125
[No Abstract] [Full Text] [Related]
8. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
Gonzalez DE; Foresto RD; Ribeiro AB
Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
[TBL] [Abstract][Full Text] [Related]
9. Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
Thompson J; Schacht S; Rothenberg F
Cardiol Clin; 2019 Aug; 37(3):335-343. PubMed ID: 31279427
[TBL] [Abstract][Full Text] [Related]
10. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.
Weir MR
Postgrad Med; 2016; 128(3):290-8. PubMed ID: 26821720
[TBL] [Abstract][Full Text] [Related]
11. Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK
Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920
[TBL] [Abstract][Full Text] [Related]
12. New Medications for the Treatment of Diabetes.
Garg SK; Giordano D
Diabetes Technol Ther; 2019 Feb; 21(S1):S160-S171. PubMed ID: 30785325
[No Abstract] [Full Text] [Related]
13. Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential
.
Vallianou NG; Trigkidis K; Kazazis C
Clin Nephrol; 2017 Apr; 87 (2017)(4):212-216. PubMed ID: 28177279
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
Scheen AJ; Piérard L; Krzesinski JM; Paquot N
Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
[TBL] [Abstract][Full Text] [Related]
15. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
Hiramatsu T; Ito H; Okumura S; Asano Y; Iguchi D; Furuta S
Diab Vasc Dis Res; 2020; 17(6):1479164120971220. PubMed ID: 33371732
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
Bloch MJ
J Am Soc Hypertens; 2016 Mar; 10(3):186-7. PubMed ID: 27408945
[No Abstract] [Full Text] [Related]
17. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
Bajaj HS; Brown RE; Bhullar L; Sohi N; Kalra S; Aronson R
Diabetes Metab; 2018 Dec; 44(6):493-499. PubMed ID: 30149145
[TBL] [Abstract][Full Text] [Related]
19. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
Lupsa BC; Inzucchi SE
Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
[TBL] [Abstract][Full Text] [Related]
20. London buses: A cardiovascular outcome trial equivalent?
Grant PJ
Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
